A costly and widely used medication for patients on hemodialysis is no better at reducing mortality than lower-cost alternatives, according to the findings of a new study.
In the largest prospective randomized study to date comparing patients on hemodialysis who were given sevelamer hydrochloride (Renagel, Genzyme Corporation, Cambridge, Mass) or a calcium-based binder to treat hyperphosphatemia, the Dialysis Clinical Outcomes Revisited (DCOR) trial, researchers found that all-cause mortality was the same in the group taking sevelamer (267 deaths) and the group taking a calcium-based binder (275 deaths) (Suki WN et al. Kidney Int. doi:10.1038/sj.ki.5002466 [published online ahead of print August 29, 2007]).
Mitka M. Study Probes Best Choice of Drug to Reduce Phosphate in Patients on Dialysis. JAMA. 2007;298(17):1995-1996. doi:10.1001/jama.298.17.1995